S&P 500 Financials Sector SEC Filings — March 23, 2026

23-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 23, 2026, announcing the issuance of a press release regarding the integration of RAD devices into the Immix platform by AITX's RAD and Immix entities. No financial metrics, performance comparisons, or quantitative impacts were disclosed in the filing.

23-03-2026

PMGC Holdings Inc. (ELAB) entered into Amendment No. 5 on March 17, 2026, to its consulting agreement with GB Capital Ltd (wholly owned by CEO/CFO/Director Graydon Bensler), setting the annual consultant fee at $300,000 effective January 1, 2026. The company also entered into a similar Amendment No. 5 with Northstrive Companies Inc. (wholly owned by Chairman Braeden Lichti), setting the annual fee at $360,000 effective the same date. These amendments restate fee provisions of prior agreements originally dated October 25, 2024, with no other changes.

• ·Original consulting agreements dated October 25, 2024
• ·Prior amendments dated April 3, 2025; August 12, 2025; October 16, 2025
• ·Filing date: March 23, 2026

23-03-2026

Mission Produce, Inc. furnished an updated investor presentation via Form 8-K on March 20, 2026, for the 38th Annual ROTH Conference on March 23-24, 2026. The presentation addresses the proposed transaction with Calavo, including forward-looking statements on benefits, integration risks, regulatory approvals, and stockholder votes, alongside standard safe harbor disclaimers. No specific financial metrics or period-over-period comparisons were disclosed in the filing.

• ·Securities: Common Stock (AVO, par value $0.001) and Series A Junior Participating Preferred Stock (par value $0.001), traded on NASDAQ Global Select Market
• ·Form 8-K filed under Rule 425 (M&A Communications)
• ·Joint Proxy Statement/Prospectus and Form S-4 referenced for proposed transaction

23-03-2026

Nortech Systems Incorporated entered into a new Credit and Security Agreement with Associated Bank, National Association on March 20, 2026, establishing a revolving credit facility of up to $15M (with $1.5M letter of credit sublimit) and a $2.2M term loan, replacing the prior facility set to mature in August 2026. The new facility and term loan mature in March 2029, bear interest at base rate or Term SOFR plus 2.00% (revolver) or 2.25% (term loan), and are secured by substantially all U.S. assets. It includes standard covenants such as a minimum Fixed Charge Coverage Ratio of 1.10:1.00 and typical events of default.

• ·Existing credit facility scheduled to mature in August 2026
• ·New facility secured by substantially all U.S. assets
• ·Financial covenant: Fixed Charge Coverage Ratio of at least 1.10 to 1.00 (EBITDA adjusted less unfunded capex over fixed charges)

23-03-2026

CECO Environmental Corp. presented at the 38th Annual Roth Conference on its proposed merger with Thermon Group Holdings, Inc., offering $10 cash per Thermon share plus 0.684 CECO shares, with expected cost synergies >$40M (75% by end-2027) and ~2.5x net leverage at close. CECO standalone delivered FY25 revenue of $774M (up ~39% YoY from $558M) and Adjusted EBITDA of $90M (up ~43% YoY from $63M), though gross profit margins remained flat at 35%; FY26 guidance raised to $925-975M revenue (+23% YoY midpoint) and $115-135M Adjusted EBITDA (+38% YoY midpoint) on a $6.5B+ pipeline. The deal requires shareholder and regulatory approvals amid risks including integration challenges and potential failure to achieve synergies.

• ·CECO cumulative stock return ~700% since March 2020 vs. S&P 500 ~73% and Russell 2000 ~24%.
• ·Pipeline growth ~430% since full year 2021; orders ~415% and revenue ~290%.
• ·End-market mix FY25E: 50% highly engineered, 25% standard/lightly engineered, 25% short cycle/parts/aftermarket.
• ·CECO stock price $55.28 as of March 20, 2026 close.

23-03-2026

BRC Inc. disclosed via 8-K that an unauthorized Board director stated on the 'Forged In America' podcast that the company will probably achieve approximately $450M in revenue, along with references to future gross margins beyond FY2026 and longer-term profiles. The company clarified the director was not authorized to speak on financial performance and reaffirmed its official FY2026 guidance of at least 7% net revenue growth over FY2025's $398.3M. No declines or flat metrics were reported, maintaining a conservative outlook versus the director's higher projection.

• ·Podcast name: Forged In America
• ·Previous guidance issued: March 2, 2026 earnings release and March 3, 2026 investor conference call
• ·Date of earliest event reported: March 22, 2026

23-03-2026

Enpro Inc.'s DEF 14A proxy statement for the April 29, 2026 annual meeting details 2025 executive compensation, highlighting adjusted EBITDA of $276.5M (between target and maximum levels) and Cash Flow ROIC of 30.5% (near maximum), driving annual performance plan payouts at 130.5% of target despite investments in growth initiatives and semiconductor market volatility. Named executive officers received payouts from 58.7% to 143.6% of base salary, with 2025 long-term incentives allocated 30% to Performance Share Awards (rTSR vs. S&P SmallCap 600 Capital Goods Index), 30% to stock options, and 40% to RSUs vesting over three years ending December 31, 2027.

• ·Annual shareholder meeting scheduled for April 29, 2026.
• ·2025 long-term incentive performance cycle ends December 31, 2027.

23-03-2026

Honeywell International Inc. announced the results as of March 19, 2026, and pricing for its tender offers to purchase certain existing debt securities, with settlement expected on March 24, 2026. Upon settlement, the special mandatory redemption obligation on $10B aggregate principal amount of Honeywell Aerospace senior notes (including $1.25B 3.900% due 2028, $1.25B 4.000% due 2029, and others up to 4.950% due 2036) will cease. This supports the planned Spin-Off of Honeywell Aerospace Inc.

• ·Tender offer results cutoff: 5:00 p.m. New York City time on March 19, 2026.
• ·Press releases on tender offer results (Exhibit 99.1) and pricing (Exhibit 99.2) dated March 20, 2026.
• ·Honeywell common stock and various senior notes traded on Nasdaq Stock Market LLC.

23-03-2026

On March 17, 2026, Volato Group, Inc. received a notice from NYSE American LLC indicating non-compliance with continued listing standards under Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide due to stockholders’ equity below $2.0M (for losses in two of three recent fiscal years) and $4.0M (for losses in three of four recent fiscal years). The Company must submit a compliance plan by April 16, 2026, to regain standards by December 17, 2026, or face delisting proceedings, though there is no immediate impact on trading of its Class A Common Stock (SOAR) on NYSE American. Warrants (SOARW) trade on OTC Markets Group, Inc.

• ·Company address: 1954 Airport Road, Suite 124, Chamblee, GA 30341
• ·Telephone: 844-399-8998
• ·SEC Commission File Number: 001-41104
• ·IRS Employer Identification No.: 86-2707040
• ·Emerging growth company status: Yes

23-03-2026

AMERICAN REBEL HOLDINGS INC (formerly CUBESCAPE INC) filed an 8-K on March 23, 2026, covering Items 3.03 (material modifications to rights of security holders), 5.03 (charter or bylaws amendments), 7.01 (Regulation FD disclosure), and 9.01 (financial statements and exhibits). The filing is categorized under Charter/Bylaws Amendments as a material event, with no quantitative financial data, period-over-period comparisons, improvements, declines, or flat performance disclosed in the provided metadata. No additional positive or negative metrics are available.

• ·Company CIK: 0001648087
• ·SIC: 3490 - MISCELLANEOUS FABRICATED METAL PRODUCTS
• ·State of Incorporation: NV; Location: TN; Fiscal Year End: December 31
• ·Mailing/Business Address: 218 3RD AVENUE NORTH, #400, NASHVILLE TN 37201
• ·Phone: 833-267-3235

23-03-2026

On March 20, 2026, Liberty Energy Inc. (LBRT) released an updated investor presentation via Regulation FD disclosure, covering its strategic focus and outlook for the distributed power business. The presentation is available on the company's Investor Relations website at https://investors.libertyenergy.com/news-and-events/events-and-presentations. No specific financial metrics or performance data were disclosed in the filing.

23-03-2026

Verde Clean Fuels, Inc. appointed George Burdette, its current CFO since October 2024, as new CEO, succeeding Ernie Miller who is stepping down to pursue other opportunities but will remain as a senior advisor. The company engaged Roth Capital Partners as a financial advisor to evaluate strategic alternatives, including potential merger, sale, or other transactions involving its STG+® technology, as part of ongoing restructuring and cost reduction initiatives. While positioned as a step to maximize shareholder value through capital-lite opportunities, the process has no set timetable and no assurance of any transaction.

• ·George Burdette previously served as CFO of Arbor Renewable Gas and Itafos, and head of project finance at First Solar.
• ·No binding agreements entered for strategic alternatives; company does not intend to disclose developments unless required.
• ·Announcement dated March 20, 2026; SEC filing March 23, 2026.

23-03-2026

Quest Resource Holding Corporation (QRHC) filed an 8-K on March 23, 2026, furnishing an updated Investor Presentation dated March 2026 as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. This presentation replaces in its entirety all prior presentations, including the one filed on November 12, 2025. The filing contains no specific financial metrics or performance data.

• ·Date of earliest event reported: March 20, 2026
• ·Replaces prior presentation from November 10, 2025 (filed November 12, 2025)

23-03-2026

Heritage Financial Corporation detected a cybersecurity incident on March 2, 2026, involving unauthorized access and exfiltration of files from an internal employee file share server that may contain personal information. While customer accounts, systems, and operations were unaffected with no disruptions to business continuity, the company has launched an investigation with external forensic and legal advisors and notified regulators, law enforcement, and its cyber insurance carrier. As of the March 20, 2026 report date, the incident has not been determined to be material or likely to impact financial condition or results of operations.

• ·Affected system taken offline to contain the incident.
• ·Incident reported under Item 8.01 Other Events in Form 8-K filed March 23, 2026.

23-03-2026

U.S. GoldMining Inc. filed Amendment No. 1 to its Form 8-K on March 23, 2026, solely to update and include the consents of Qualified Persons Sue Bird (Exhibit 23.1) and Steven Klohn (Exhibit 23.2) for the previously reported 'Whistler Gold-Copper Project, S-K 1300 Technical Report Summary and Initial Assessment with Economic Analysis' (dated March 19, 2026, effective March 2, 2026). The amendment makes no other changes to the Original Report filed on March 19, 2026, which included the technical report as Exhibit 99.1. No financial metrics or period-over-period comparisons are provided in this filing.

• ·Registrant is an emerging growth company.
• ·Principal executive offices: 1188 West Georgia Street, Suite 1830, Vancouver, BC, Canada, V6E 4A2.
• ·Telephone number: (604) 338-9788.
• ·IRS Employer Identification No.: 37-1792147.
• ·Commission File Number: 001-41690.

23-03-2026

Ormat Technologies, Inc. announced a proposed private offering of $600M aggregate principal amount of Series A Convertible Senior Notes due 2031 and $150M of Series B Convertible Senior Notes due 2031, with options for initial purchasers to buy up to an additional $90M Series A and $22.5M Series B. Net proceeds, along with $25M cash on hand, will fund repurchase of a portion of its outstanding 2.50% convertible senior notes due 2027 via private negotiations, up to $25M in common stock repurchases to offset dilution, and general corporate purposes. The notes are unsecured senior obligations with semiannual interest payments starting September 15, 2026, maturing March 15, 2031.

• ·Series B Notes optional repurchase date: March 15, 2027 at 100% principal plus accrued interest.
• ·Notes redeemable at company's option on or after March 20, 2029, if stock price >=130% of conversion price for specified period.
• ·Conversion prior to November 15, 2030 under certain circumstances; cash, shares, or combination for excess over principal.
• ·Offerings to qualified institutional buyers under Rule 144A; unregistered under Securities Act.

23-03-2026

Core Laboratories Inc. reported total revenue of $527M in 2025, up a modest 0.5% YoY from $524M, driven by 2.9% growth in services to $399M, while product sales declined 6.3% to $127M. Operating income fell 3.6% to $56M and net income attributable to the company decreased 5.5% to $30M with diluted EPS at $0.63, down 4.5%. Free cash flow was $26M, down sharply from $44M, though long-term debt net was reduced to $110M from $126M.

• ·Current ratio declined to 2.02:1 in 2025 from 2.16:1 in 2024.
• ·Debt to EBITDA ratio improved to 1.20:1 in 2025 from 1.37:1 in 2024.
• ·Credit facility balance reduced to $3M in 2025 from $18M in 2024.
• ·Senior Notes maturities: Series A 2021 at 4.09% due Jan 12, 2026 ($45M); others unchanged.
• ·Accounts receivable allowance for credit losses increased to $6.3M in 2025 from $3.2M in 2024.
• ·Inventories decreased to $54M in 2025 from $59M in 2024.

23-03-2026

Aterian, Inc. reported net revenue of $69.0M for the year ended December 31, 2025, down 30.4% YoY from $99.0M, driven by a 32.4% decline in direct sales while wholesale revenue grew 88.4% to $3.2M; however, most product segments declined sharply, including housewares down to $14.9M from $22.5M and heating/cooling to $13.9M from $26.4M, with essential oils remaining nearly flat. Gross profit fell 36.3% to $39.2M amid a drop in gross margin to 56.8% from 62.1%, and despite operating expenses decreasing to $57.1M, a $3.8M impairment loss contributed to operating loss widening 52.0% to $18.0M. Net loss increased 60.0% to $19.0M.

• ·Heating, cooling and air quality revenue: $13.9M in 2025 (down from $26.4M in 2024)
• ·Kitchen appliances revenue: $8.5M in 2025 (down from $9.6M in 2024)
• ·Health and beauty revenue: $10.6M in 2025 (down from $13.5M in 2024)
• ·Essential oils and related accessories revenue: $12.1M in 2025 (down slightly from $12.7M in 2024)
• ·Interest expense, net declined 10.3% to $0.9M

23-03-2026

Cartesian Growth Corp III reported net income of $6.2M for the year ended December 31, 2025, driven by $7.4M in interest income from investments held in the Trust Account totaling $283.4M from 27.6M Class A ordinary shares at ~$10.27 per share, with total assets increasing to $284.2M from $0.3M at December 31, 2024. However, the company recorded an operating loss of $1.2M from general and administrative costs, and shareholders' deficit stood at $13.2M, improved from $17.6K but still negative. Total liabilities rose to $14.0M, primarily due to a $13.1M deferred underwriting fee.

• ·Company inception date: October 29, 2024
• ·Filing date: March 23, 2026
• ·Auditor: Independent Registered Public Accounting Firm (PCAOB ID Number 199)

23-03-2026

Finwise Bancorp reported net income of $16.1M for the year ended December 31, 2025, up 26% from $12.7M in 2024, fueled by non-interest income surging 160% to $58.5M and net interest income growing 23% to $72.2M, alongside total assets expanding 31% to $977M and deposits rising 38.5% to $755M. However, provisions for credit losses ballooned to $38.6M from $11.6M, non-interest expenses increased 33% to $70.3M, net interest margin declined to 9.23% from 9.99%, and total equity to assets ratio fell to 19.8% from 23.3%. Segment-wise, BaaS contributed strongly with $10.5M net income, but Traditional Banking net income was $2.9M.

• ·BaaS segment net income $10.5M, Traditional Banking $2.9M, Treasury/Other $2.7M.
• ·Loans held-for-investment net grew 20.9% to $541.6M.
• ·Credit enhancement income $23.9M (up 21,453%), but related expenses surged (servicing +112,135%, guarantee +111,846%).
• ·Average yield on loans held-for-investment declined to 12.17% from 12.27%, net of credit enhancement to 10.35% from 12.27%.

23-03-2026

SUNation Energy reported FY2025 sales of $71.9M, up 26% YoY from $56.9M, driven by residential contracts (+31% to $40.2M in one segment and +31% to $21.0M in another), with gross profit rising 35% to $27.5M; however, SG&A expenses remained flat at ~$27M (38% of sales), total operating expenses declined only 11%, and the company posted a net loss of $10.9M (improved 31% YoY from $15.8M but widened by fair value losses on warrant liability of $7.5M). Balance sheet strengthened with cash surging to $7.2M from $0.8M, current liabilities dropping 43% to $15.4M, and stockholders' equity rising to $24.3M from $8.5M, aided by debt reductions.

• ·No goodwill or intangible impairments in FY2025 (vs $3.1M and $0.75M in FY2024)
• ·Fair value remeasurement of warrant liability loss of $7.5M in FY2025 (673% worse YoY)
• ·Reverse stock split 1-for-200 effective April 21, 2025; prior periods adjusted
• ·Basic net loss per share improved to -$4.38 from -$10,110.93 (adjusted)

23-03-2026

Ashford Hospitality Trust's total revenue declined 5.8% YoY to $1.10B in 2025 from $1.17B in 2024, driven by lower rooms revenue ($826M, down 7.3%) and flat other segments, while total hotel expenses fell 5.8% to $768M providing some relief. Net loss attributable to the company widened significantly to $180M from $60M, with operating income dropping 55% to $116M and Adjusted EBITDAre decreasing 6.2% to $221M amid higher impairment charges ($68M, up 14%). RevPAR slipped 0.9% to $131.68 despite occupancy rising slightly to 70.3%, and Adjusted FFO worsened to -$34M from -$23M.

• ·Total hotel revenue $1.10B in 2025 (down 5.8% YoY), Rooms revenue $826M (down 7.3%), Food and beverage $208M (down 2.4%).
• ·Impairment charges $68M in 2025 (up 14% YoY from $59M).
• ·Stockholders’ equity deficit deepened to -$626M from -$419M.
• ·Debt associated with hotels in receivership $273M at Dec 31 2025 (down from $315M).

23-03-2026

Technology & Telecommunication Acquisition Corp (TETE) has filed a DEFM14A proxy statement dated March 23, 2026, for an extraordinary general meeting on or after the record date of February 25, 2026, to approve a Business Combination with Super Apps and Holdings, resulting in PubCo listing on Nasdaq as RADB, subject to approval. Post-merger ownership remains stable across minimum, mid-point, and maximum redemption scenarios, with Holdings shareholders at 85.3-85.4% (basic) or 58.4% (fully diluted), Sponsor at 10.7%/9.3%, and public shareholders at a low 1.6-1.7%/29.7%; a $5.0M PIPE is committed (with $16.0M interest), but the trust account holds only $142,275.91 as of February 23, 2026, signaling potentially high redemptions. The merger will make PubCo a controlled company with Bradbury Private Investment XVIII holding 34.5% voting power, and includes Sponsor forfeitures of 447,952 shares and contingent shares to MobilityOne.

• ·Non-Redemption Agreements dated January 19, 2025 (150,000 shares forfeited) and April 14, 2025 (297,952 shares forfeited), terminated but forfeiture obligation survives.
• ·TETE incorporated November 8, 2021; Class A shares, warrants, units listed on OTC Pink Current January 23, 2025 under TETEF, TETWF, TETUF.
• ·Nasdaq listing approval for RADB is a closing condition, waivable by Holdings and Super Apps.
• ·Shareholder meeting requests for additional documents by March 19, 2026.

23-03-2026

News Corporation filed an 8-K disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing stock repurchase program, under which the company is authorized to acquire up to $1 billion in aggregate of its Class A (NWSA) and Class B (NWS) common stock. The disclosures, attached as Exhibits 99.1 and 99.2, fulfill daily ASX reporting requirements for any transactions under the program. No specific repurchase transactions or amounts were detailed in the filing itself.

• ·Class A Common Stock trades as NWSA on Nasdaq Global Select Market
• ·Class B Common Stock trades as NWS on Nasdaq Global Select Market
• ·Event date: March 20, 2026; Filing date: March 23, 2026

23-03-2026

1606 Corp. amended and restated a promissory note to its former CEO Gregory Lambrecht, increasing the principal from $1.22M (issued Nov 1, 2024) to $1.89M effective Dec 31, 2025, due to additional loans provided by him. The note matures Dec 31, 2025 and is convertible at the holder's option into common stock at a 25% discount to the closing bid price, subject to a 9.99% beneficial ownership limit, creating a direct financial obligation with potential shareholder dilution.

• ·Board of directors approved the issuance on March 17, 2026.
• ·Filed as Exhibit 4.1: Amended and Restated Promissory Note dated December 31, 2025.

23-03-2026

Faraday Future Intelligent Electric Inc. announced that the SEC has concluded its years-long investigation into 2021 PIPE and SPAC-related transactions with no enforcement action against the Company, founder and Co-CEO YT Jia, President Jerry Wang, or other team members, removing a major regulatory overhang. This provides clarity to pursue strategic financing, partnerships, Nasdaq compliance within 180 days without a reverse split, and focus on EAI vehicles and robotics. However, forward-looking statements highlight ongoing risks including liquidity shortages, potential delisting if share price falls below $0.10 for 10 days, substantial dilution needs, and execution challenges on vehicle deliveries and robotics.

• ·Nasdaq compliance notice received March 20, 2026, granting 180-day period to meet $1 minimum bid price without reverse stock split.
• ·SEC investigation originated from independent director probe in October 2021 related to SPAC merger.
• ·FF 91 deliveries began in 2023; Super One deliveries planned for 2026; Embodied AI Robotics sales beginning in 2026.

23-03-2026

Apogee Therapeutics announced positive 52-week maintenance data from Part A of the Phase 2 APEX trial of zumilokibart (APG777) in moderate-to-severe atopic dermatitis, demonstrating durable EASI 75 maintenance of 75% (3-month dosing) and 85% (6-month) among Week 16 responders, with overall responses of 88% and 81%, and deepening efficacy across endpoints. However, overall vIGA 0/1 responses were lower for 6-month dosing at 52% versus 72% for 3-month, EASI 90 at 48% versus 75%, and EASI 100 at 19% versus 41%. Zumilokibart was well-tolerated with 71.4% TEAEs, rare serious events (0.8%), and low discontinuations (3.4%), supporting Phase 3 initiation in 2H 2026 for a potential $50B AD market launch in 2029.

• ·APEX Part B 16-week induction data expected Q2 2026
• ·Phase 3 trial initiation for zumilokibart in AD expected 2H 2026
• ·Phase 1b APG279 vs. DUPIXENT 24-week readout on track for 2H 2026
• ·Further clinical trial plans for zumilokibart in asthma and eosinophilic esophagitis to be announced 2H 2026
• ·Conference call and webcast held March 23, 2026 at 8:00 a.m. ET

23-03-2026

Revenue from concentrate sales increased 64.6% YoY to $42.4M in 2025 from $25.8M in 2024, driven by 665 more ounces sold and higher realized gold prices of $3,583/oz versus $2,307/oz, boosting gross profit to $26.2M (61.8% margin) from $13.0M (50.3%) and net income to $16.6M from $8.8M. However, cash costs per ounce rose to $1,026 from $910 (+$117), all-in sustaining costs (AISC) per ounce climbed to $1,892 from $1,474 (+$418), exploration expenses surged $4.7M, and investing activities showed a $61.5M outflow versus $20.8M prior year.

• ·Realized gold price $3,583.43/oz in 2025 vs $2,306.86/oz in 2024.
• ·Cash and equivalents ended 2025 at $9.9M, up from $1.1M.
• ·Mineral resources estimated using $2,580/oz three-year trailing average gold price.

23-03-2026

Cardinal Health appointed Patricia A. Hemingway Hall as Board Chair effective immediately, succeeding Gregory B. Kenny upon his retirement; Kenny had served on the Board since 2007 and as Chairman since 2018. CEO Jason Hollar expressed gratitude for Kenny's leadership during periods of transformation and confidence in Hemingway Hall's continuation of strong governance. The company reaffirmed confidence in its fiscal 2026 outlook ahead of third quarter earnings release on April 30.

• ·Ms. Hemingway Hall served on the Board since 2013 and as Chair of the Governance and Sustainability Committee for nearly seven years.
• ·Former CEO role of Ms. Hemingway Hall: President and Chief Executive Officer of Health Care Service Corporation.
• ·Third quarter fiscal 2026 earnings release scheduled for April 30, 2026.

23-03-2026

Ingredion Incorporated announced the retirement of director Gregory B. Kenny effective March 23, 2026, after serving since 2005, stating it was not due to any disagreement with company operations, policies, or practices. The Board elected Siobhán Talbot, former CEO of Glanbia plc, as an independent director effective April 1, 2026; she will receive standard non-management director compensation including cash and equity retainers.

• ·Gregory B. Kenny informed company of retirement decision on March 20, 2026.
• ·Siobhán Talbot, age 62, served Glanbia plc for 31 years, including as CEO from November 2013 to December 2023.
• ·Talbot serves on CRH plc board and audit committee.
• ·Director compensation details in proxy statement filed April 9, 2025.

23-03-2026

Sealed Air Corporation announced on March 23, 2026, that it has received all regulatory approvals required to complete its pending acquisition pursuant to the Agreement and Plan of Merger dated November 16, 2025, with Sword Purchaser, LLC (affiliated with Clayton, Dubilier & Rice, LLC) and Sword Merger Sub, Inc. The transaction is expected to close in April 2026, subject to the satisfaction of remaining customary closing conditions. A press release detailing the update is attached as Exhibit 99.1.

• ·Merger agreement dated November 16, 2025
• ·Registrant details: Delaware incorporation, Commission File Number 1-12139, IRS EIN 65-0654331, principal offices at 2415 Cascade Pointe Boulevard, Charlotte, North Carolina 28208

23-03-2026

ReserveOne Holdings, Inc. (Pubco) announced on March 20, 2026, the filing of a second amendment to its Form S-4 registration statement with the SEC for its proposed business combination with M3-Brigade Acquisition V Corp., following initial announcement on July 8, 2025, and prior filings on December 5, 2025, and February 17, 2026, indicating progress in the SEC review. Upon closing, subject to SEC effectiveness, shareholder approval, and other conditions, Pubco expects Nasdaq listing under 'RONE'. However, the filing highlights significant risks including potential delays or failure to close, high shareholder redemptions, cryptocurrency volatility, regulatory uncertainties, and operational challenges for the early-stage digital asset firm.

• ·SEC filing date: March 23, 2026 (Form 425)
• ·M3-Brigade tickers: NASDAQ: MBAVU, MBAV, MBAVW
• ·Expected Pubco ticker post-closing: RONE on Nasdaq
• ·ReserveOne website: www.reserveone.com
• ·M3-Brigade website: www.m3-brigade.com/m3-brigade-acquisition-iii-corp

23-03-2026

Avalo Therapeutics' 10-K shows a sharp decline in cash and equivalents to $15.9M as of Dec 31, 2025 from $134.5M in 2024, driven by a net cash decrease of $118.6M versus a $127.1M increase prior year, with operating cash use rising 5% to $51.5M and financing inflows dropping 92% to $14.6M. Total assets fell 23% to $116.5M while stockholders' equity decreased 38% to $83.0M amid a $78.3M worsening of accumulated deficit to $(448.5M). However, interest income grew 31% to $4.4M and common shares outstanding more than doubled to 18.5M.

• ·Executives adopted Rule 10b5-1 trading plans in November 2025 for future sales of up to 471,718 shares total, expiring mid-to-late 2026.
• ·Derivative liability increased to $18.0M non-current (from $8.1M) with $9.5M negative fair value change in 2025.
• ·Series C Preferred Stock outstanding decreased to 18,792 shares from 24,896.

23-03-2026

RenovoRx announced an oversubscribed $10M at-market private placement of ~10.6M common shares at $0.938/share (insiders at $1.029/share) plus milestone warrants for ~5.3M shares, anchored by life science institutional investors and participated in by senior management and board members. Proceeds will accelerate RenovoCath commercialization, which generated $900k in revenue over the first nine months of 2025 from initial purchase orders including repeat and new NCI-designated centers, and advance the Phase III TIGeR-PaC trial to full enrollment by mid-2026 with data in 2027. The financing supports goals of increasing revenue, reducing cash burn, and achieving cash-flow breakeven, with warrants tied to a $1.5M quarterly revenue milestone.

• ·Private placement priced at $0.938 per share for investors ($1.029 for executives/board); warrant exercise at $1.751 ($1.933 for executives/board), exercisable immediately, expire 30 days after $1.5M quarterly revenue announcement or March 30, 2029
• ·Expected closing March 20, 2026, subject to customary conditions
• ·First commercial RenovoCath purchase orders received December 2024
• ·RenovoCath has FDA clearance and Orphan Drug Designation (via IAG) for pancreatic and bile duct cancer

23-03-2026

Coeur Mining completed its acquisition of New Gold Inc. on March 20, 2026, significantly boosting 2026 consolidated production guidance to 680,000-815,000 oz gold (80% increase from 419,046 oz in 2025), 18.7-21.9M oz silver (from 17.9M oz), and 50-65M lbs copper, incorporating nine months from New Afton and Rainy River. The company authorized a $750M share repurchase program, an inaugural $0.02/share semiannual dividend starting Q2 2026, and a new $1.0B revolving credit facility replacing the prior $400M facility. Updated reserves and resources for New Afton and Rainy River support mine life extensions to 2032 and 2035, respectively, with strong projected free cash flows.

• ·New Afton 2025 reserves: 36.2M tonnes (780k oz gold, 2.1M oz silver, 591M lbs copper)
• ·Rainy River 2025 reserves: 2.2M oz gold, 5.6M oz silver
• ·New Afton K-Zone M&I resources: 47.6M tonnes (715k oz gold, 2.9M oz silver, 606M lbs copper)
• ·2026 cash income and mining taxes: $475-600M
• ·Effective tax rate: 30-36%

23-03-2026

Insmed Incorporated announced positive topline results from the Phase 3b ENCORE study of ARIKAYCE plus multidrug therapy vs placebo plus multidrug therapy in new MAC lung infection patients, meeting the primary endpoint with a 17.77 vs 14.66 point improvement in Respiratory Symptom Score at Month 13 (p=0.0299) and superiority in multiplicity-controlled secondary endpoints like culture conversion by Month 6 (87.8% vs 57.0%). However, the PROMIS Fatigue T-score change was not statistically significant (-5.07 vs -4.27, p=0.2900), and ARIKAYCE showed higher treatment-emergent adverse events including dysphonia (58.7% vs 8.5%), severe TEAEs (15.0% vs 10.4%), and discontinuations (14.6% vs 8.5%). The company plans sNDA submission to FDA and PMDA in H2 2026 for label expansion.

• ·Time to Culture Conversion: Median Month 2 (ARIKAYCE) vs Month 3 (placebo), hazard ratio 2.03 (p<0.0001)
• ·Study completion rates: 90.6% (ARIKAYCE) vs 93.4% (placebo)
• ·Treatment discontinuation rates: 18.3% (ARIKAYCE) vs 11.8% (placebo)
• ·Conference call held March 23, 2026 at 8:00 a.m. ET

23-03-2026

AParadise Acquisition Corp., a SPAC listed on Nasdaq (APADU, APAD, APADR), released its PFIC Annual Information Statement for fiscal year 2025 (Jan 1 to Dec 31, 2025) on March 23, 2026, reporting per-share per-day ordinary earnings of $0.000605 and no net capital gains or distributions. The statement assists US shareholders with potential QEF elections under IRC Section 1295 and confirms the company may be treated as a PFIC. No other financial metrics or period comparisons were provided.

• ·Company incorporated November 9, 2022 in British Virgin Islands.
• ·Taxpayer Identification Number: N/A.
• ·Principal address: The Sun’s Group Center, 29th Floor, 200 Gloucester Road, Wan Chai, Hong Kong.
• ·Emerging growth company: Yes.

23-03-2026

YHN Acquisition I Limited deposited $150,000 into its trust account on March 19, 2026, to extend the deadline for completing an initial business combination from March 19, 2026, to June 19, 2026. This provides the SPAC with an additional three months to identify and consummate a target acquisition. No other financial impacts or performance metrics were disclosed.

• ·Securities registered: YHNAU (Units), YHNA (Ordinary Share), YHNAR (Rights) on Nasdaq
• ·Principal executive offices: 2/F, Hang Seng Building, 200 Hennessy Road, Wanchai, Hong Kong

23-03-2026

Pyxis Oncology's total revenues declined 14% YoY to $13.9M in 2025 from $16.1M, primarily due to the complete loss of $8.1M royalty revenues despite growth in sale of royalty rights (+38% to $11.0M) and new milestone revenue of $2.8M. While total operating expenses fell 7% to $98.3M (no repeat of $21.0M impairment), R&D expenses rose 25% to $73.7M, resulting in a net loss widening to $79.6M from $77.3M; cash and equivalents dropped to $15.4M from $19.5M with higher operating cash burn of $63.5M.

• ·Rule 10b5-1 trading arrangement adopted by Lara Sullivan on Dec 22, 2025, for sale of 411,845 shares, effective until March 31, 2027.
• ·Marketable debt securities declined to $51.4M from $107.5M as of Dec 31, 2025.
• ·Stock-based compensation expense was $11.8M in 2025, down from $12.9M in 2024.
• ·Weighted average shares outstanding increased to 62.1M from 58.4M.

23-03-2026

Victory Capital Holdings, Inc. (VCTR) issued a press release on March 23, 2026, in connection with its previously announced proposal to acquire Janus Henderson Group plc. The filing contains standard forward-looking statements highlighting risks such as regulatory approvals, stockholder consents, potential litigation, business disruptions, and failure to realize expected synergies or benefits. No specific financial terms, deal progress, or quantitative updates on the proposed transaction are disclosed.

• ·Securities registered: Common Stock, Par Value $0.01, Trading Symbol VCTR on NASDAQ
• ·Reference to Company's 2025 annual meeting proxy statement filed with SEC on March 28, 2025

23-03-2026

Progressive Corporation reported strong 2025 performance with 10% companywide policies in force growth and 12% net premiums written growth, alongside a debt-to-capital ratio of 18.5% and 99th percentile ranking in employee engagement surveys among 70,000 employees. Over the past five years, it delivered 26.0% annualized return on net income and 25.2% on comprehensive income, outperforming the S&P 500 by 1.6x and peers by 1.2x in total shareholder return, with 15% annualized net premiums written growth and 8.3% underwriting margin versus the industry's -0.4% margin and 7% growth. The proxy seeks shareholder approval for 11 director nominees, advisory vote on executive compensation, and ratification of PricewaterhouseCoopers LLP as auditors for 2026.

• ·Annual Meeting of Shareholders: May 8, 2026, 10:00 a.m. Eastern Time, virtual via virtualshareholdermeeting.com/PGR2026
• ·Record date for voting: March 13, 2026
• ·Shareholder votes: Elect 11 directors for one-year terms; advisory approval of executive compensation; ratify PricewaterhouseCoopers LLP as independent auditors for 2026

23-03-2026

Two Harbors Investment Corp. announced via press release that its ad hoc committee determined CrossCountry Mortgage, LLC's unsolicited cash proposal to acquire all outstanding common shares for $10.70 per share constitutes a 'Company Superior Proposal' under the existing merger agreement with UWM Holdings Corporation dated December 17, 2025, with notice delivered to UWMC on March 21, 2026. The Company also received a higher unsolicited $10.75 per share cash proposal from an unnamed third party, deemed likely to lead to another superior proposal. This development creates uncertainty around the prior UWMC merger, potentially benefiting shareholders with higher bids but introducing deal risks and litigation possibilities.

• ·Merger agreement dated December 17, 2025, by and among the Company, UWM Acquisitions 1, LLC, and UWM Holdings Corporation.
• ·Press release attached as Exhibit 99.1.
• ·Filing includes forward-looking statements with risks related to transaction completion, stockholder approval, and market impacts.

23-03-2026

Cabaletta Bio, Inc. reported a widened net loss of $167.9M for the year ended December 31, 2025, up 45% from $115.9M in 2024, primarily due to a 38% increase in total operating expenses to $172.2M driven by 47% higher R&D spending at $142.7M. Cash and cash equivalents fell 49% to $83.0M from $164.0M, with operating cash use rising 49% to $131.1M, though financing activities provided $100.3M mainly from stock issuances that nearly doubled shares outstanding to 100.5M. Total assets declined to $165.1M from $185.0M, with stockholders' equity dropping to $112.1M.

• ·Auditor emphasis of matter on accrued clinical trial expenses totaling $5.3M as of Dec 31, 2025 due to estimation uncertainty.
• ·Interest income declined 40% to $6.0M from $10.0M.
• ·Investing activities used $50.3M net cash in 2025 vs providing $47.3M in 2024, including $99.0M in investment purchases.
• ·Stock-based compensation increased 8% to $20.9M.

23-03-2026

Xilio Therapeutics reported Q4 2025 collaboration and license revenue of $13.7M, up significantly from $1.7M in Q4 2024, and full-year revenue of $43.8M versus $6.3M in 2024, driving a Q4 net income of $10.4M compared to a $13.1M loss and a reduced full-year net loss of $35.0M from $58.2M; cash position strengthened to $137.5M from $55.3M. However, R&D expenses rose to $18.1M in Q4 from $8.8M and $56.0M for the year from $41.2M, while G&A increased to $7.4M in Q4 from $6.5M and $29.7M annually from $24.8M. Pipeline advances include XTX501 on track for mid-2026 IND and masked T cell engagers progressing, with cash runway extended to end of 2027.

• ·Plans for XTX501: IND submission mid-2026, Phase 1 initiation H2 2026, initial data H2 2027.
• ·PSMA/STEAP1 masked T cell engager: development candidate nomination Q2 2026.
• ·CLDN18.2 masked T cell engager preclinical data at AACR April 17-22, 2026.
• ·Efarindodekin alfa Phase 2 option data package to Gilead H1 2027.
• ·Masked T cell engagers and XTX501 IND applications planned for 2027.